Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856154 | 1.00 | MEN1 (0.33) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL8339207 | 0.82 | MEN1 (0.35) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL26280261 | 0.82 | MEN1 (0.35) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL22790826 | 0.82 | MEN1 (0.35) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL25705179 | 0.82 | MEN1 (0.31) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL26405823 | 0.82 | KDM4E (0.39) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL25826746 | 0.82 | KDM4E (0.39) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL19631974 | 0.82 | NR1I2 (0.39) | BLMPMP22HSD17B10KDM4ENR1I2 | |
| SCHEMBL25229442 | 0.80 | BLM (0.35) | BLMPMP22HSD17B10KDM4E | |
| SCHEMBL25208953 | 0.80 | BLM (0.35) | BLMPMP22HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157298-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYCLICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYLICS, INC. A DELAWARE CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | F13B, HABP2, F7 | MEN1 2580/4885KMT2A 1024/4885BLM 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.